Company
Moderna, Inc.
Headquarters: Cambridge, MA, United States
Founded: September 2010
Employees: 2,700
CEO: Mr. Stephane Bancel
Market Cap
$16.31 Billion
USD as of Jan. 1, 2025
Moderna, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Company Description
Moderna, Inc. is a biotechnology company, specialized in vaccine technology based on messenger RNA. It is notably famous for producing one of the first vaccines against Covid-19, and it is also developing and patenting other vaccine candidates for seasonal flu, HIV, the Nipah virus, and a second COVID-19 vaccine.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | $5.08 B |
| EBITDA | $-2,361,999,872 |
| Gross Profit TTM | $-1,400,000,000 |
| Profit Margin | -43.77% |
| Operating Margin | -3.76% |
| Quarterly Revenue Growth | 1.70% |
Stocks & Indices
Moderna, Inc. has the following listings and related stock indices.
Stock: NASDAQ: MRNA wb_incandescent
Stock: BMV: MRNA wb_incandescent
Stock: Bovespa: M1RN34 wb_incandescent
Stock: FSX: 0QF wb_incandescent
Product & Services
Moderna COVID-19 vaccine
Key People
Founder(s): Derrick Rossi Timothy A. Springer Robert S. Langer Kenneth R. Chien Noubar Afeyan
Stéphane Bancel, CEO Stephen Hoge, President David Meline, CFO Noubar Afeyan, Chairman Robert S. Langer, Director Paul Sagan, Director